Design and Analysis of Bioavailability and Bioequivalence Studies
From MaRDI portal
Recommendations
Cited in
(12)- Optimum experimental designs for comparative bioavailability studies
- Confidence region approach for assessing bioequivalence and biosimilarity accounting for heterogeneity of variability
- The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trials
- scientific article; zbMATH DE number 747024 (Why is no real title available?)
- scientific article; zbMATH DE number 1278892 (Why is no real title available?)
- Bioequivalence and statistics in clinical pharmacology.
- Bioequivalence Studies in Drug Development
- A new confidence interval for the ratio of two normal means and comparisons
- Improved test procedure and sample size calculation for assessing similarity in two-group comparative studies with heterogeneous variances
- Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs
- The use of asymmetric distributions in average bioequivalence
- On assessing bioequivalence and interchangeability between generics based on indirect comparisons
This page was built for publication: Design and Analysis of Bioavailability and Bioequivalence Studies
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5503757)